Brokers Set Expectations for Theravance Biopharma, Inc.’s FY2024 Earnings (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at Zacks Research decreased their FY2024 earnings per share estimates for Theravance Biopharma in a report issued on Monday, April 15th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings per share of ($0.89) for the year, down from their previous forecast of ($0.87). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.83) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at ($0.33) EPS and FY2026 earnings at $0.84 EPS.

A number of other equities research analysts have also issued reports on TBPH. BTIG Research initiated coverage on Theravance Biopharma in a research report on Friday, April 12th. They set a “buy” rating and a $21.00 target price on the stock. Evercore ISI downgraded Theravance Biopharma from an “outperform” rating to an “inline” rating in a report on Monday, January 8th.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $9.52 on Wednesday. Theravance Biopharma has a 1 year low of $8.21 and a 1 year high of $11.98. The business’s fifty day moving average is $8.98 and its two-hundred day moving average is $9.66. The stock has a market capitalization of $462.29 million, a P/E ratio of -9.81 and a beta of 0.36.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The business had revenue of $17.57 million during the quarter, compared to analyst estimates of $17.49 million.

Institutional Trading of Theravance Biopharma

Hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its position in Theravance Biopharma by 2.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 37,916 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 948 shares during the last quarter. UBS Group AG grew its stake in shares of Theravance Biopharma by 45.0% in the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,101 shares in the last quarter. Legal & General Group Plc increased its holdings in Theravance Biopharma by 2.6% in the second quarter. Legal & General Group Plc now owns 58,904 shares of the biopharmaceutical company’s stock worth $534,000 after buying an additional 1,516 shares during the last quarter. Royal Bank of Canada raised its position in Theravance Biopharma by 33.8% during the second quarter. Royal Bank of Canada now owns 6,532 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 1,649 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Theravance Biopharma by 10.5% during the third quarter. Principal Financial Group Inc. now owns 18,637 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 1,764 shares in the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.